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Abstract Clinical variables and several gene signature
profiles have been investigated for the prediction of (dis-
tant) recurrence in several trials. These molecular markers
are significantly correlated with overall and late distant
recurrences. Here, we retrospectively explore whether age
and body mass index (BMI) affect the prediction of these
molecular scores for distant recurrence in postmenopausal
women with hormone receptor-positive breast cancer in the
transATAC trial. 940 postmenopausal women for whom
the Clinical Treatment Score (CTS), immunohistochemical
markers (IHC4), Oncotype Recurrence Score (RS), and the
Prosigna Risk of Recurrence Score (ROR) were available
were included in this retrospective analysis. Conventional
BMI groups were used (N = 865), and age was split into
equal tertiles (N = 940). Cox proportional hazard models
were used to determine the effect of a molecular score for
the prediction of distant recurrence according to BMI and
age groups. In both the univariate and bivariate analyses,
the effect size of the IHC4 and RS was strongest in women
aged 59.8 years or younger. Trends tests for age were
significant for the IHC4 and RS, but not for the CTS and
ROR, for which most prognostic information was added in
women aged 60 years or older. The CTS and ROR scores
added significant prognostic information in all three BMI
groups. In both the univariate and bivariate analyses, the
IHC4 provided the most prognostic information in women
with a BMI lower than 25 kg/m2, whereas the RS did not
add prognostic information for distant recurrence in
women with a BMI of 30 kg/m2 or above. Molecular
scores are increasingly used in women with breast cancer
to assess recurrence risk. We have shown that the effect
size of the molecular scores is significantly different across
age groups, but not across BMI groups. The results from
this retrospective analysis may be incorporated in the
identification of women who may benefit most from the use
of these molecular scores, but our findings need further
evaluation before these scores can be used in clinical
decision making.
Keywords Molecular scores  Prognostic information 
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Introduction
Breast cancer is the most common cancer in women, and
its incidence has increased over the past few years. Most
women will be diagnosed with an oestrogen receptor (ER)-
positive tumour, for which endocrine therapy will improve
their outcome substantially [1]. The risk of a recurrence is
specifically high for women with ER-negative breast can-
cer in the first 5 years after diagnosis. In contrast, women
with ER-positive breast cancer remain at risk for recur-
rence even after 5 years of endocrine therapy, with an
estimated annual excess rate of 2 % for at least 15 years.
In recent years, the development and use of multi-gene
signatures for the identification of women at high risk of
recurrence have increased noticeably. The 21-gene Onco-
type Dx recurrence score (RS) [2] has been developed to
& Ivana Sestak
i.sestak@qmul.ac.uk
1 Centre for Cancer Prevention, Wolfson Institute of
Preventive Medicine, Queen Mary University, Charterhouse
Square, London EC1M 6BQ, UK
2 Academic Department of Biochemistry, Breakthrough Breast
Cancer Centre, Royal Marsden Hospital, London, UK
3 NanoString Technologies, Seattle, USA
4 Genomic Health Inc., Redwood City, USA
123
Breast Cancer Res Treat (2016) 159:71–78
DOI 10.1007/s10549-016-3868-y
classify women with early breast cancer into risk categories
for recurrence and has been validated in several cohorts
[3]. The RS improved risk stratification in postmenopausal
patients in the transATAC (Arimidex, Tamoxifen Alone or
Combined) trial [3]. Furthermore, the prognostic precision
of RS was enhanced by incorporating classical clinico-
pathological parameters, clinical treatment score (CTS)
[4, 5]. In the same transATAC trial, similar prognostic
information was derived from four immunohistochemically
measured markers (ER, progesterone receptor (PgR), Ki67
and HER2) integrated into the immunohistochemical
markers (IHC4) score [4]. The Prosigna assay, based on the
PAM50 gene signature, was developed to determine the
intrinsic subtype of a tumour and a Risk of Recurrence
Score (ROR) that is correlated with the probability of
distant recurrence [6, 7]. The Prosigna ROR score was
shown to add significant prognostic information over
standard clinicopathological variables in the transATAC
trial [8] and the ABCSG-8 trial [9]. In a recent publication
[10], a combined analysis of these two trials showed that
the ROR predicted late distant recurrence beyond that of
clinical parameters.
Other molecular signatures, such as the EndoPredict
[11], Breast Cancer Index [12], Mammaprint [13, 14], have
also been developed for the identification of breast cancer
patients who are at high risk of a recurrence. However, all
the above signatures have in common that apart from
clinicopathological features, no other non-clinical risk
factors have been taken into account when their prognostic
ability was developed and investigated. It is well known
that age, body mass index (BMI), previous hormone
replacement therapy (HRT) are the risk factors for the
development of breast cancer [15–19]. It is therefore
important to assess the value of incorporation of these
parameters when analysing the prognostic ability of multi-
gene signatures for the prediction of recurrence. The
transATAC study offers a great opportunity to analyse the
impact of baseline risk factors on the prediction of recur-
rence, as there is a median of 10 years follow-up on all
patients, and data on the prognostic relevance of four
clinical/multi-gene signatures are available.
Methods
The main Anastrozole Tamoxifen Alone or in Combination
(ATAC) trial evaluated the efficacy and safety of anastro-
zole, tamoxifen, or the combination in postmenopausal
women with localised breast cancer [20]. For the trans-
ATAC protocol, formalin-fixed paraffin-embedded blocks
from primary tumours were collected [21]. For this retro-
spective analysis, 940 women (84.0 %) from the trans-
ATAC study with hormone receptor-positive breast cancer
who did not receive chemotherapy, randomised to either
tamoxifen or anastrozole, and for whom we had data on all
four scores available, were included. The IHC4 and CTS
were developed on the transATAC dataset and have been
described in detail previously [4]. In brief, the CTS contain
information on nodal status, grade, tumour size, age, and
treatment received. The IHC4 score was used as calculated
previously [4]. The 21-gene-based Oncotype Dx RS was
developed in women with hormone receptor-positive,
node-negative breast cancer treated with tamoxifen [2].
The signature is based on 16 breast cancer-specific genes
and five reference genes, including information on prolif-
eration, oestrogen-related genes, invasion, HER2, and other
factors [2]. The Prosigna ROR score is based on a 50-gene
test [6, 7] and is derived from an expression profile of the
50 genes analysed on the NanoString nCounter Dx analysis
system and also includes information on tumour size. A
46-gene subset of the PAM50 genes plus tumour size was
used to calculate a predefined ROR score [22].
The primary objective of this study was to determine if
non-clinical baseline factors affect the prognostic perfor-
mance of clinical and multi-gene signatures for the pre-
diction of distant recurrence in the transATAC study.
Baseline (risk) factors included in this analysis were age
and BMI (conventional groups:\25 kg/m2, 25–30 kg/m2,
[30 kg/m2), previous HRT use, smoking status, hys-
terectomy, treatment with radiotherapy, and surgery type
(mastectomy vs. breast conserving surgery). The time from
randomisation to first distant recurrence was the prospec-
tively defined primary endpoint. Death before distant
recurrence was treated as a censoring event. The associa-
tion between clinical/multi-gene scores, baseline risk fac-
tors, and distant recurrence was assessed using hazard
ratios derived from Cox proportional hazard models with
associated 95 % confidence intervals (CI). For multivariate
analyses, each multi-gene signature was added separately
to CTS to determine the prognostic information added by
that score within a baseline risk group. All Hazard ratios
(HR) are for a change between the 25th and 75th percentile
of the continuous scores. Changes in likelihood ratio values
(LRv2) were used to measure and compare the relative
amount of information of one score compared to the other.
P values were two-sided, based on normal approximation,
and all confidence intervals were at the 95 % level. Anal-
yses were performed using STATA version 13.1 (College
Station, Texas, USA).
Results
940 postmenopausal women with hormone receptor-posi-
tive primary breast cancer were included in this analysis.
Baseline demographics are presented in Table 1. Median
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age was 63.6 years (IQR 57.9–70.7) and median BMI was
26.6 kg/m2 (IQR 23.5–29.9). For this analysis, we used age
tertiles and conventional BMI groups to determine the
impact of prognostic performance of the scores in each
group. All other baseline factors were used as dichotomous
variables in our analyses and are shown in Table 1.
Age
Overall, age as a continuous variable was a significant risk
factor for distant recurrence in all patients (for a change in
one standard deviation (SD): HR = 1.73 (1.36–2.20),
P\ 0.001), and those with node-negative/HER2-negative
disease (for a change in one SD: HR = 1.92 (1.28–2.89),
P = 0.002). Table 2 shows the prognostic performance of
each score according to age tertile at baseline. In the uni-
variate analysis, the largest effect sizes for the CTS were
seen in the youngest [HR = 3.23 (2.22–4.69)] and the
oldest age group [HR = 2.98 (2.23–3.97)], whereas the
CTS was less prognostic for women between the ages of
59.8 and 68.2 years (Fig. 1). However, an interaction
test for age and CTS was statistically not significant
(Pinteraction = 0.056). For the ROR, age added most prog-
nostic information for women in the 2nd tertile
[HR = 4.51 (2.87–7.10)], and the score was less predictive
for distant recurrence in the other two age groups in the
univariate analysis (Pinteraction = 0.055) (Table 2). A dif-
ferent picture was seen for the IHC4 and Oncotype RS,
where the largest effect sizes and the most prognostic value
were observed in the youngest age group (HR = 3.01
(1.99–4.53) and HR = 2.16 (1.62–2.87), respectively).
Both scores were significantly less prognostic for dis-
tant recurrence in women aged 59.8 years or older
(Table 2). A significant interaction for age and IHC4 was
observed (Pinteraction = 0.033), but not so for age and RS
(Pinteraction = 0.056). For the bivariate analyses, each score
was added to the CTS to see what additional prognostic
information was provided by each score in each age group.
Results are shown in Table 2 and graphically in Fig. 1. The
ROR score added significant prognostic information when
adjusted for the CTS for women between the ages of 59.8
and 68.2 years [HR = 3.24 (2.02–5.20)], but was less pre-
dictive in the youngest age group and did not add any sig-
nificant prognostic information for women older than
68.2 years of age, HR = 1.33 (0.92–1.93) (Table 2; Fig. 1).
For the IHC4 and Oncotype RS, similar results were seen as
in the univariate analysis. In the bivariate analysis, both
scores showed the largest effect size in the youngest age
group (Table 2), with significant decreasing prognostic
performance with increasing age (Ptrend for both B 0.0001)
(Fig. 1).
BMI
BMI as a continuous variable was not a significant risk
factor for distant recurrence (for a change in one SD:
HR = 1.12 (0.90–1.38), P = 0.3). In the univariate anal-
ysis, CTS provided similar amount of prognostic infor-
mation across all three BMI groups (Table 2). For the ROR
score, the most prognostic information for distant recur-
rence in the univariate analysis was added for women with
a BMI between 25 and 30 kg/m2. Different results were
observed for the IHC4 and Oncotype RS, where the largest
effect sizes were seen in the lowest BMI tertile (HR = 2.37
(1.70–3.31), HR = 1.74 (1.35–2.25), respectively), and
decreasing prognostic information was added with
Table 1 Baseline demographics and number of distant recurrence
Number of women (N = 940) Number of distant recurrence (%)
Age (years), median (IQR) 63.6 (57.9-70.7)
1st tertile (N = 314), median (IQR) 55.7 (53.1-57.9) 33 (10.5)
2nd tertile (N = 313), median (IQR) 63.6 (61.6-65.7) 51 (16.3)
3rd tertile (N = 314), median (IQR) 73.5 (70.7-76.8) 70 (22.4)
BMI (kg/m2), median (IQR) 26.6 (23.5-29.9)
B25 (N = 314), median (IQR) 22.5 (21.2-23.8) 49 (15.6)
25–30 (N = 339), median (IQR) 27.4 (26.1-28.6) 59 (17.4)
[30 (N = 212), median (IQR) 32.8 (31.2-34.9) 34 (16.0)
Prior HRT (%) 340 (36.2 %) 41 (12.1)
Never smokers (%) 477 (50.7 %) 79 (16.6)
Hysterectomy (%) 208 (22.1 %) 33 (15.9)
Radiotherapy (%) 639 (68.0 %) 103 (16.1)
Mastectomy (%) 390 (41.5 %) 94 (24.1)
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increasing BMI, although a trend test across BMI groups
was not significant (Table 2). No significant interaction
was observed for any score with BMI (all Pinterac-
tion[ 0.05). In the bivariate analysis, the most prognostic
value for distant recurrence by all three scores was found in
women with a BMI between 25 and 30 kg/m2, and all
scores were significantly less predictive in women with a
BMI over 30 kg/m2 (Table 2; Fig. 2). To account for the
inclusion of age in the CTS, we performed all analyses
without adjusting the multi-gene signatures for the CTS
and observed very similar results (Table 2).
The risk factor analysis according to HRT use, radio-
therapy, smoking status, hysterectomy, or mastectomy did
not reveal any differences in the prognostic performance of
the scores (data not shown).
Discussion
Many multi-gene signatures have been developed for the
prediction of (distant) recurrence in women with early
hormone receptor-positive breast cancer. They all have
shown to add significant prognostic information for
recurrence in different clinical settings [2, 4, 8]. These
scores have been developed for a variety of different
clinicopathological groups, e.g. women with ER-positive
breast cancer or for those with node-negative disease.
However, no other non-clinical factors have been taken
into account when assessing the prognostic value of these
multi-gene scores.
Our results show that age is an important non-clinical
factor when assessing the prognostic performance of clin-
ical, immunohistochemical, and multi-gene scores. Age
was a significant risk factor for distant recurrence. Similar
results were reported by the TEAM trialist group [23],
which reported an increased risk of distant recurrence in
elderly patients with hormone receptor-positive breast
cancer treated with endocrine therapy alone. In the trans-
ATAC trial, elderly women were less adherent to their
treatment allocation compared with younger women, which
may partly explain the higher risk of distant recurrence.
However, older women also had higher oestrogen and Ki67
levels than younger women, which could also contribute to
an increase risk of recurrence. Increased levels of oestrogen
and Ki67 in older women were also observed by Paik et al.
[2], but in contrast they found that older women had fewer
recurrences than younger women.
In our study, the prognostic performance of all scores
was lowest for the older patients in the univariate and
bivariate analyses. This decrease in performance with age
was especially pronounced for the IHC4 and the Oncotype
Table 2 Hazard ratios (HRs) and likelihood ratio tests (LRv2) for all four scores according to age tertiles and BMI group for the univariate and
bivariate analyses
Univariate analysis CTS ROR IHC4 RS
Age (years) (tertiles) HR (95 % CI) LRv2 HR (95 % CI) LRv2 HR (95 % CI) LRv2 HR (95 % CI) LRv2
B59.8 (N = 314) 3.23 (2.22-4.69) 34.24 3.87 (2.21-6.78) 23.21 3.01 (1.99-4.53) 25.08 2.16 (1.62-2.87) 22.55
59.8–68.2 (N = 313) 1.76 (1.51-2.05) 41.23 4.51 (2.87-7.10) 44.74 1.67 (1.23-2.26) 10.00 1.39 (1.16-1.66) 9.64
[68.2 (N = 313) 2.98 (2.23-3.97) 50.17 1.83 (1.28-2.60) 11.39 1.64 (1.25-2.15) 12.05 1.38 (1.11-1.73) 7.20
Bivariate analysis (in addition to CTS)
Age (years) (tertiles) DLRv2 DLRv2 DLRv2
B59.8 (N = 314) 2.07 (1.12-3.82) 5.50 2.23 (1.46-3.40) 13.63 1.78 (1.32-2.39) 13.32
59.8–68.2 (N = 313) 3.24 (2.02-5.20) 24.95 1.62 (1.17-2.24) 7.61 1.28 (1.04-1.57) 4.69
[68.2 (N = 313) 1.33 (0.92-1.93) 2.28 1.55 (1.16-2.07) 8.11 1.26 (1.00-1.58) 3.62
Univariate analysis
BMI (kg/m2) (tertiles)
B25 (N = 314) 2.54 (1.97-3.30) 42.32 3.01 (1.88-4.84) 21.54 2.37 (1.70-3.31) 23.76 1.74 (1.35-2.25) 15.47
25–30 (N = 339) 2.10 (1.67-2.60) 38.89 3.21 (2.21-4.67) 38.16 1.72 (1.31-2.26) 13.88 1.49 (1.26-1.76) 15.48
[30 (N = 212) 2.64 (2.02-3.45) 44.43 4.23 (2.31-7.74) 24.5 1.65 (1.11-2.46) 5.57 1.18 (0.85-1.64) 0.87
Bivariate analysis (in addition to CTS)
BMI (kg/m2) (tertiles) DLRv2 DLRv2 DLRv2
B25 (N = 314) 1.92 (1.19-3.09) 7.29 2.02 (1.43-2.84) 15.09 1.54 (1.18-2.02) 9.02
25–30 (N = 339) 2.33 (1.55-3.51) 16.62 1.66 (1.24-2.22) 10.75 1.43 (1.18-1.72) 10.77
[30 (N = 212) 2.40 (1.21-4.74) 6.63 1.43 (0.92-2.23) 2.34 1.07 (0.77-1.48) 0.15
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Dx RS, for which the most prognostic information was
added in women aged 59.8 years or younger, with a sta-
tistically significant trend observed with increasing age.
This trend toward decreased performance of multi-gene
signatures with increasing age may be explained in part by
a difference in tumour biology of older patients. In elderly
women, immunosenescence plays an important role
[24, 25] in tumourigenesis and progression. This altered
immune state of older women appears to lead to altered
tumour biology and may also result in worse performance
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Fig. 1 Forest plot for prediction of distant recurrence according to signature and age groups
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of multi-gene signatures than in younger women. In addi-
tion, as was mentioned above, significantly higher levels of
oestrogen and Ki67 were observed in older women, and
these older women were also more likely to have poorly
differentiated tumours than younger women. Both the
IHC4 and Oncotype RS incorporate information on Ki67
and ER levels, and the observed increase in these levels in
older women might explain the diminishing effect of these
scores with increasing age. Our results suggest that multi-
gene signatures may not accurately capture the risk of
recurrence in older women, but further validation to con-
firm this finding is needed.
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Fig. 2 Forest plot for prediction of distant recurrence according to signature and BMI groups
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A similar picture, but less pronounced, was observed for
BMI. The IHC4 and Oncotype RS were most prognostic in
leaner women (BMI \25 kg/m2), whereas the Prosigna
ROR score added most value in women with a BMI
between 25 and 30 kg/m2. A recent study by Creighton
et al. investigated the impact of obesity on the expression
profiles of 662 tumours and found that obesity was corre-
lated with patterns of gene expression, specifically gene
signatures for insulin-like growth factor (IGF) signalling
and to a lesser extent lower levels of ER [26]. In our study,
obese women also had lower levels of ER, although the
difference compared with leaner women was not statisti-
cally significant. It is possible that the changes in gene
expression associated with obesity may be related to the
decreased prognostic performance of immunohistochemical
and multi-gene scores. Taking this finding together with the
fact that obese women with early-stage breast cancer have a
poorer prognosis [27], the use of these multi-gene signa-
tures in this patient group should be investigated further.
Strengths of this analysis include the large sample size,
long-term follow-up for all patients, and the availability of
all scores for all patients. We performed the comparison of
standardised prognostic assays routinely used in the clinic
in a well-characterised set of samples. Limitations included
that all women are from the United Kingdom, and therefore
our results may not be translated for populations in other
countries. All demographics were only collected at base-
line, and we do not have any data on change of BMI with
follow-up time. Furthermore, we have to acknowledge that
this analysis was of a retrospective nature. Lastly, in a
number of cases, multiple comparisons were made and
caution is needed in interpreting those results. However, in
the univariate analysis, the majority of tests and compar-
isons were highly statistically significant at the 1 % level,
even after correction for multiple comparisons (nominal
P\ 0.001). For subgroup analyses, heterogeneity tests are
more important [28], and no heterogeneity was observed
between subgroups.
In summary, our results from this retrospective analysis
show that factors other than tumour biology and clinical
characteristics are important when assessing recurrence
risk by multi-gene signatures in women with hormone
receptor-positive breast cancer. Patient’s biologic charac-
teristics need to be taken into account as well for an ade-
quate risk categorisation by these scores. Further validation
of our results is needed before they can be implemented in
clinical decision making.
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